Primary Lung Adenocarcinoma With Trophoblastic Differentiation and Usage of Gefitinib for Postoperative Recurrence: Report of a Case With a Review of the Literature

Yasumichi Yamamoto, Toshiya Toyazaki, Shinji Kosaka


We report a rare and very aggressive case of lung carcinoma showing trophoblastic differentiation, so-called choriocarcinoma, for which postoperative recurrence was treated using gefitinib. A 51-year-old woman with pathological stage IIA adenocarcinoma with trophoblastic differentiation underwent left lower lobectomy with lymph node dissection and postoperative adjuvant chemotherapy, remaining tumor-free for 10 months until the detection of the brain metastasis. Gefitinib was administered, as the tumor was positive for epidermal growth factor receptor mutation, and this resulted in a 12-month progression-free period. The patient died 37 months after surgery due to multiple metastases in the brain, ovary and uterus. This is the first case report using gefitinib to the lung carcinoma showing trophoblastic differentiation. A review of the literature on lung cancer with trophoblastic differentiation suggested that a chemotherapeutic regimen for primary lung cancer other than germ cell tumor might be suitable for the lung carcinoma with trophoblastic differentiation.

J Med Cases. 2016;7(11):484-487


Lung cancer; Adenocarcinoma; Trophoblastic differentiation; Gefitinib; Choriocarcinoma

Full Text: HTML PDF

Browse  Journals  


Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics


World Journal of Oncology

Gastroenterology Research

Journal of Hematology


Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity


Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research


Journal of Neurology Research

International Journal of Clinical Pediatrics



Journal of Medical Cases, monthly, ISSN 1923-4155 (print), 1923-4163 (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)

This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website:   editorial contact:
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.

Disclaimer: The views and opinions expressed in the published articles are those of the authors and do not necessarily reflect the views or opinions of the editors and Elmer Press Inc. This website is provided for medical research and informational purposes only and does not constitute any medical advice or professional services. The information provided in this journal should not be used for diagnosis and treatment, those seeking medical advice should always consult with a licensed physician.